AI Consensus Investment Thesis
Johnson & Johnson (JNJ) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
NEUTRAL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
SELL ALL$254
-5.9%-3.9% incl. dividends5-Year
NEUTRAL$294
+8.9%+20.8% incl. dividendsLatest flagship insight
Valuation Reality Confronts Resilient Healthcare Cash Flow Compounding
There is high consensus that operational execution remains robust across oncology and cardiovascular intervention. However, sharp divergence persists regarding whether an elevated valuation multiple can withstand five percent Treasury yields, biosimilar margin erosion, and ongoing tort liabilities over the forward five-year investment horizon.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Elon Musk (Visionary), Universal Investor (Polymath), Machiavelli (Insider), Michael Burry (Vulture), Sherlock Holmes (Whistleblower), Warren Buffett (Value Purist), J.P. Morgan (Titan), Superintelligence (Anthropologist), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Johnson & Johnson at the forecast anchor (2026-09-18): $12,082 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 2.1% net dividend yield for Johnson & Johnson.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 262.10 | -2.92% | -2.92% | Elevated sovereign yields near five percent trigger institutional profit-taking in high-multiple defensive equities. Multiple compression outweighs solid quarterly operational volume, initiating a necessary valuation reset as flight-to-safety flows stabilize across broader asset markets. |
| Q1 2027 | 256.20 | -2.25% | -5.11% | Full-year financial guidance confirms revenue crossing the hundred-billion milestone, but conservative outlooks highlight accelerating biosimilar erosion in legacy immunology. Slower forward net income compounding forces a downward recalibration of premium earnings multiples. |
| Q2 2027 | 254.57 | -0.63% | -5.71% | Progress on claimant voting tallies for the proposed talc settlement reduces tail legal uncertainty, establishing fundamental valuation support. Commercial uptake of next-generation oncology biologics helps cushion residual generic discounting across European markets. |
| Q3 2027 | 254.16 | -0.16% | -5.86% | Disposal or separation of the orthopaedics franchise clarifies the remaining portfolio profile and financing capacity. Stable cardiovascular procedure volumes balance initial settlement cash disbursements, keeping quarterly price performance tightly contained. |
| Q4 2027 | 255.45 | +0.51% | -5.38% | Accelerating volume in subcutaneous oncology formulations and specialized catheter platforms lifts quarterly operating margins. Management's capital return commitments and disciplined buybacks reinforce price stability heading into the fiscal year-end close. |
| Q1 2028 | 255.38 | -0.03% | -5.41% | Initial implementation of federally negotiated drug prices trims gross realizations on exposed biopharmaceutical lines. The market distinguishes top-line volume growth from retained operating cash margins, producing range-bound price action during quarterly consolidation. |
| Q2 2028 | 259.43 | +1.59% | -3.91% | Positive clinical trial telemetry and expanding international regulatory clearances for interventional cardiovascular platforms support earnings expectations. Maturing launch infrastructure lowers incremental commercialization expenses, driving modest quarterly equity appreciation. |
| Q3 2028 | 259.43 | +0.00% | -3.91% | Financing sensitivities among hospital procurement budgets temporarily moderate equipment placements. Nevertheless, non-discretionary procedural consumable demand and expanding hematology indications preserve robust underlying cash generation, limiting downside equity drift. |
| Q4 2028 | 262.97 | +1.37% | -2.60% | The shrinking top-line weight of expired legacy biologics allows newer immunology launches to drive visible consolidated growth. Announcement of the sixty-sixth consecutive dividend raise provides reliable valuation support among conservative institutional income allocators. |
| Q1 2029 | 261.84 | -0.43% | -3.02% | Expiration of Section 232 tariff carve-outs and statutory price caps introduce temporary margin headwinds. Sell-side models absorb these policy adjustments, prompting brief multiple digestion before operational mitigations take full effect. |
| Q2 2029 | 266.02 | +1.60% | -1.47% | Domestic manufacturing optimizations absorb trade policy friction while high-margin cell therapy adoption expands globally. Demonstrating earnings durability amidst policy transitions rebuilds institutional confidence, generating measured upward share price momentum. |
| Q3 2029 | 268.68 | +1.00% | -0.49% | Approaching composition-of-matter patent expirations on cornerstone oncology assets prompt proactive portfolio positioning. Market concerns are partially tempered by high patient retention on proprietary subcutaneous formulations and expanding robotic surgery adoption. |
| Q4 2029 | 272.63 | +1.47% | +0.98% | Completion of multi-year biopharmaceutical supply-chain restructurings yields tangible manufacturing efficiencies. Annual free cash generation easily covers recurring capital commitments and opportunistic equity repurchases, lifting per-share valuation into year-end. |
| Q1 2030 | 275.83 | +1.17% | +2.16% | Annual financial reporting showcases consolidated revenue expanding comfortably above historical thresholds with stable operating margins. Steady operational execution proves post-cliff resilience, prompting constructive earnings revisions across fundamental healthcare funds. |
| Q2 2030 | 278.19 | +0.86% | +3.04% | Broadened international adoption of interventional cardiology devices and robotic surgical systems accelerates MedTech earnings compounding. Expanding high-margin procedural utilization insulates total cash flows from regional pharmaceutical price controls. |
| Q3 2030 | 279.74 | +0.56% | +3.61% | Demographic aging trends across major developed economies sustain robust baseline volume growth for orthopedic and cardiovascular interventions. Highly predictable operating results support an orderly, low-volatility advance in the quoted equity value. |
| Q4 2030 | 283.88 | +1.48% | +5.14% | Disciplined balance sheet redeployment through ongoing share cancellations and rising dividend payouts enhances total shareholder return. Deep commercial entrenchment across clinical hospital workflows reinforces the company's defensive competitive moat. |
| Q1 2031 | 287.24 | +1.18% | +6.39% | Maturing commercial contributions from oral targeted peptides and next-generation bispecific antibodies establish unassailable therapeutic dominance. Sustainable mid-single-digit operating growth validates management's long-term portfolio regeneration strategy. |
| Q2 2031 | 290.69 | +1.20% | +7.67% | Advanced automated manufacturing facilities lower per-unit biologic production costs, supporting operating profit margins near peak cycle levels. Steady cash conversion maintains robust liquidity, driving gradual equity appreciation toward fair value. |
| Q3 2031 | 294.02 | +1.14% | +8.90% | The five-year transition cycle concludes with valuation multiples fully normalized near historical medians. High-quality operational earnings growth successfully absorbs past multiple compression, delivering stable capital preservation and reliable distributions. |
The base-case investment thesis resolves as an economic tug-of-war between durable business compounding and mechanical multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. Operationally, the enterprise is successfully replacing legacy exclusivity losses through double-digit volume expansion in oncology anchors, newly approved targeted oral peptides, and high-barrier cardiovascular devices, supporting mid-single-digit top-line compounding toward $120 billion by 2031. However, starting valuations near 31x trailing earnings and an equity free cash flow yieldfree cash flow yieldFree cash flow divided by market value, showing cash generation relative to the asset price.View full glossary entry below 3% create severe discount-rate vulnerability against persistent 5% risk-free sovereign benchmarks. As multiple normalization toward historical 18x to 20x parameters offsets underlying net income gains, capital appreciationcapital appreciationThe increase in the market value of an asset over a specific investment horizon.View full glossary entry will be muted, leaving dividends and share retirements to deliver the bulk of total shareholder returns.
Key insights
- Replacing expiring pharmaceutical exclusivity demands massive operational reinvestment, which dilutes incremental cash conversion even when reported adjusted earnings per share expand steadily.
- Policy frictions, specifically statutory Medicare price negotiations and expiring Section 232 tariff carve-outs in early 2029, place a structural ceiling on gross realizations.
- Portfolio optimization, including the planned orthopaedics separation, mechanically improves group growth and margin mix, yet cannot fully insulate equity multiples from macroeconomic yield competition.
This business is successfully growing its sales by launching cutting-edge cancer drugs, innovative oral immunology pills, and advanced heart devices that help offset declining sales from older medicines facing generic competition. However, because the stock has surged to a very expensive valuation, investors paying today's high prices face an uphill battle. With government bonds offering safe yields near five percent, the company's stock multiple is likely to shrink over time, which means stock price gains will probably be modest even as underlying company profits steadily rise.
Key insights
- Strong sales of new medicines are replacing older off-patent drugs, but high development costs keep total cash flow growth modest.
- Government drug price caps and changing import tariffs will limit how much profit the company can make on mature treatments.
- Investors should expect returns to come primarily from reliable quarterly dividend payments rather than rapid share price growth.
Deep Dive
Prevailing market sentiment treats the enterprise as an unassailable defensive sanctuary, bidding shares to over thirty times earnings following post-separation restructuring, strong oncology volume, and headline progress on a proposed $5.5 billion talc settlement. This consensus relies on the assumption that non-cyclical healthcare demand and $100 billion in revenue insulate the stock from interest rate gravity, complacently treating rich valuation multiples as permanent.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market sentiment treats the enterprise as an unassailable defensive sanctuary, bidding shares to over thirty times earnings following post-separation restructuring, strong oncology volume, and headline progress on a proposed $5.5 billion talc settlement. This consensus relies on the assumption that non-cyclical healthcare demand and $100 billion in revenue insulate the stock from interest rate gravity, complacently treating rich valuation multiples as permanent.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially overestimates valuation durability, creating measurable stock overpricing. The market's blind spot is treating defensive pharmaceutical stability as immune to capital-market discount rates when benchmark Treasuries yield near five percent. Crucially, investors overlook that replacing expiring high-margin biologic rents requires heavy ongoing commercialization expenditure and absorbs statutory price concessions, meaning mid-single-digit operational growth cannot sustain premium multiples once safe-haven flight flows unwind.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst is the disclosure of full-year financial guidance bridges revealing margin dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry from biosimilar discounting and statutory Medicare price concessions, paired with actual settlement cash disbursements. Over the next two to six quarters, institutional allocators comparing mid-single-digit earnings expansion against five percent risk-free sovereign alternatives will rebalance capital out of crowded defensive equities, compelling multiple mean reversionmean reversionThe statistical tendency of a variable to move back toward a long-run average, when such a stable average exists.View full glossary entry toward historical conglomerate norms.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Greed
- Volatility
- Moderate
- Cycle position
- Overshoot
While reports unanimously agree that defensive crowding has produced a valuation overshoot, they diverge on whether multiple deflation will cause an immediate nominal drawdown or be absorbed gradually through steady multi-year operational earnings compounding.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of sticky inflation, policy rates near four percent, and ten-year Treasury yields near five percent constitutes a decisive valuation headwind. While inelastic somatic healthcare demand completely insulates patient volume from macroeconomic cyclicality, the company's thin free cash flow yieldfree cash flow yieldFree cash flow divided by market value, showing cash generation relative to the asset price.View full glossary entry leaves equity valuation acutely exposed to discount-rate competition from sovereign debtsovereign debtDebt issued or guaranteed by a national government.View full glossary entry.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive debate centers on valuation elasticity versus operational durability. One perspective argues that paying 31x trailing earnings for a five percent revenue grower during a five percent Treasury regime guarantees severe capital destructioncapital destructionA lasting loss of invested capital caused by poor returns, impairment, dilution, or uneconomic investment.View full glossary entry as multiples mean-revert. The opposing thesis contends that superior oncology execution, cardiovascular device integration, and litigation ring-fencing justify a durable scarcity premium that cushions the multiple. Resolving this disagreement requires observing full-year 2027 gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry realizations and checking whether organic sales growth exceeds six percent as Stelara biosimilar discounts accelerate.
Base-Case Forces
Event Risk ScoreModerate40/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Oncology and hematology franchise expansion | Innovation And Product | +18% | +24% | Commercial scaling of Darzalex, including rapid conversion to subcutaneous Faspro formulations, combined with earlier-line adoption of Carvykti cell therapy and bispecific antibodies, secures dominant market share in hematologic malignancies. This clinical execution generates durable, high-margin biologic cash flows exceeding $22 billion annually, successfully backfilling off-patent revenue voids. |
| Cardiovascular MedTech integration synergies | Competitive Positioning | +13% | +16% | Strategic integration of Shockwave Medical and Abiomed into the global electrophysiology infrastructure establishes commanding chokepoints in intravascular lithotripsy and mechanical circulatory support. High procedural switching costsswitching costsFinancial, operational, technical, contractual, or learning costs incurred when changing products or providers.View full glossary entry and non-deferrable clinical interventions protect segment gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry above 70%, accelerating MedTech organic top-line contributions toward seven percent annually. |
| Talc litigation liability ring fencing | Regulatory | +11% | +6.0% | Advancing a consensual $5.5 billion settlement covering approximately 76,000 ovarian cancer claimants systematically transforms open-ended tort liabilities into predictable, amortized cash disbursements. Achieving final judicial confirmation eliminates an existential institutional governance discountgovernance discountValuation gap caused by complex corporate structures and perceived poor shareholder alignment.View full glossary entry, releasing restricted balance-sheet reserves and restoring long-term credit stability without imperiling ongoing operations. |
| Fortress balance sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry capital compounding | Capital Allocation | +9.0% | +10% | Armed with a pristine AAA credit profile and annual free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry exceeding $19 billion, management executes disciplined capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry. Consistent dividend increases spanning over six decades paired with programmatic share repurchases retiring roughly one percent of floatfloatThe number of shares available for public trading in the market.View full glossary entry annually systematically cushion per-share intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry through restrictive credit cycles. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry mean reversionmean reversionThe statistical tendency of a variable to move back toward a long-run average, when such a stable average exists.View full glossary entry drag | Macroeconomic And Macrofinancial | -20% | -1.0% | Trading at an anomalous multiple above 31x trailing earnings with a sub-3% free cash flow yieldfree cash flow yieldFree cash flow divided by market value, showing cash generation relative to the asset price.View full glossary entry creates an unsustainable spread against 5% sovereign Treasury yields. As defensive safe-haven crowding subsides, mechanical multiple mean reversionmean reversionThe statistical tendency of a variable to move back toward a long-run average, when such a stable average exists.View full glossary entry toward historical 18x to 20x parameters exerts severe downward pressure on quoted equity prices. |
| Stelara biosimilar patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry erosion | Competitive Positioning | -13% | -15% | Accelerating biosimilar penetration against cornerstone immunology biologic Stelara across North American and European formularies strips billions in high-margin cash flow. Price discounts exceeding forty percent create an ongoing top-line operational drag that newer pipeline assets must expend substantial commercial capital to replace. |
| Statutory drug price negotiation mandates | Regulatory | -10% | -11% | Federal price negotiation frameworks under the Inflation Reduction Act enforce statutory discounts across major biopharma therapies, including upcoming cycles affecting key cardiovascular and oncology treatments. These mandatory concessions compress domestic gross-to-net realizations, placing an unyielding structural ceiling on pharmaceutical operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry expansion. |
| Trade policy and tariff expiry | Political And Geopolitical | -8.0% | -7.0% | Proclamation 11020 pharmaceutical tariff exemptions tied to onshoring and most-favored-nation pricing agreements carry a firm expiration date on January 20, 2029. The approaching expiration threatens import duty reversions while enforced international reference pricing structurally erodes net realizations across core biopharmaceutical franchises. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Talc settlement collapse and litigation | 30% | -21% | Claimant balloting failing to achieve the mandatory 95% threshold would void the proposed $5.5 billion settlement, remanding tens of thousands of active tort claims back to state jury dockets. Exposure to runaway punitive verdicts exceeding billions in single awards would force emergency litigation reserve additions, impairing net earnings and triggering severe multiple de-rating. |
| Commercial price control legislative expansion | 22% | -19% | Bipartisan federal legislation expanding mandatory statutory price negotiation caps from Medicare into private employer commercial insurance formularies would permanently dismantle domestic biopharma gross realizations. Slicing billions directly from core oncology and immunology revenues would structurally reduce return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry and induce violent equity derating. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Oral immunology peptide market sweep | 32% | +19% | Pivotal Phase 3 readouts and regulatory label expansions establishing oral IL-23 inhibitor icotrokinra as first-line therapy across inflammatory bowel diseases would transform autoimmune treatment paradigms. Dislodging injectable biologics with shelf-stable oral convenience would expand addressable patient volume threefold, unlocking over $8 billion in peak annual sales and driving substantial operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry accretion. |
| Ottava surgical robotics commercial ascendancy | 28% | +15% | Securing rapid commercial hospital network standardization for the Ottava soft-tissue robotic platform would break entrenched incumbent surgical monopolies. Capitalizing on Ethicon's vast hospital footprint to drive recurring proprietary instrument and digital consumable sales would accelerate MedTech division growth into double digits, triggering broad institutional multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry across the enterprise. |
Company Financial Analysis
Johnson & Johnson Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
The enterprise is demonstrating genuine top-line resilience, with annual revenues surpassing the milestone of one hundred billion dollars behind robust volume growth in flagship oncology medicines and cardiovascular devices. These expanding franchises have effectively absorbed the steep revenue drop in older blockbuster treatments like Stelara following the arrival of low-cost biosimilars. However, reported headline profits continue to be distorted by volatile legal reserves and acquisition amortizations. Beneath these accounting swings, underlying owner earnings are compounding at a stable mid-single-digit pace, backed by around twenty-two billion dollars in reconstructed trailing free cash flow that provides solid foundation for operations.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 94.2B | USD 26.8B | USD 19.7B |
| 2024 | USD 88.8B | USD 14.1B | USD 19.8B |
| 2023 | USD 85.2B | USD 35.2B | USD 18.2B |
| 2022 | USD 80B | USD 17.9B | USD 17.2B |
| 2021 | USD 78.7B | USD 20.9B | USD 19.8B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 18.8x | TTM | Native | USD / USD |
| 2024 | 25.0x | TTM | Native | USD / USD |
| 2023 | 10.8x | TTM | Native | USD / USD |
| 2022 | 26.2x | Annual | Native | USD / USD |
| 2021 | 21.9x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Operating margins have shown healthy resilience near twenty-seven percent, supported by corporate streamlining following the consumer health spin-off and favorable product mix toward high-margin cancer therapies. Disciplined administrative cost control has helped protect overall profitability despite persistent inflation in hospital labor and specialized supply chains. Looking ahead, maintaining gross margins near sixty-eight percent will become increasingly challenging. Severe biosimilar price discounting on legacy treatments alongside mandatory government Medicare price caps represent structural headwinds that sales volume gains can only partially offset, keeping a tight ceiling on further profit margin expansion.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 25.6B | 27.2% | 28.5% |
| 2024 | USD 22.1B | 24.9% | 15.8% |
| 2023 | USD 21.9B | 25.7% | 41.3% |
| 2022 | USD 21B | 26.3% | 22.4% |
| 2021 | USD 20.9B | 26.6% | 26.5% |
Balance sheet and leverage
AI Review
The enterprise preserves an elite AAA-rated balance sheet characterized by conservative financial leverage, a debt-to-equity ratio of 0.59, and interest coverage exceeding thirty-four times operating earnings. This pristine solvency profile allows management to easily absorb major acquisitions and maintain debt service without facing credit market stress. Nevertheless, significant resources are already earmarked for pending legal commitments. While the proposed five-point-five billion dollar talc settlement is well within the company's annual free cash flow capacity, funding these multi-year payouts and potential tariff-related onshoring investments will temporarily limit excess cash available for aggressive share repurchases.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 47.9B | USD 20.1B | USD 28.2B net debt | 1.03x |
| 2024 | USD 36.6B | USD 24.5B | USD 12.5B net debt | 1.11x |
| 2023 | USD 29.3B | USD 22.9B | USD 7.5B net debt | 1.16x |
| 2022 | USD 39.6B | USD 22.3B | USD 26.8B net debt | 0.99x |
| 2021 | USD 33.8B | USD 31.6B | USD 19.3B net debt | 1.35x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management maintains disciplined capital spending, directing roughly five percent of annual revenue into modernizing advanced biologic production facilities and precision medical device plants. Rather than overspending on excess physical factories, capital deployment has deliberately prioritized targeted external acquisitions like Shockwave Medical to secure proven, high-margin technologies. This capital allocation posture allows the company to replace expiring patent revenue without overextending its operational budget. The company's multi-billion-dollar domestic investment commitments focus on high-return cell therapies and surgical robotics, which should generate reliable long-term cash flow while safeguarding overall returns on invested capital.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 4.8B | USD 14.7B |
| 2024 | USD 4.4B | USD 17.2B |
| 2023 | USD 4.5B | USD 15B |
| 2022 | USD 4B | USD 14.1B |
| 2021 | USD 3.7B | USD 14.3B |
Quarterly Forecast Scenarios
Johnson & Johnson Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $253.79 | $262.66 | $264.59 | $750.26 | |
| $243.64 | $255.93 | $272.53 | $736.44 | |
| $243.87 | $253.05 | $277.98 | $743.40 | |
| $236.56 | $252.17 | $269.86 | $755.15 | |
| $229.44 | $252.00 | $280.42 | $776.22 | |
| $222.55 | $250.99 | $286.03 | $787.13 | |
| $218.10 | $253.88 | $294.61 | $802.83 | |
| $215.92 | $254.37 | $288.72 | $812.05 | |
| $215.92 | $257.09 | $294.50 | $839.18 | |
| $218.08 | $256.27 | $289.21 | $850.50 | |
| $220.26 | $260.00 | $294.81 | $872.39 | |
| $218.06 | $262.13 | $297.02 | $885.51 | |
| $220.24 | $265.60 | $305.93 | $909.56 | |
| $224.64 | $268.56 | $308.99 | $916.13 | |
| $226.89 | $271.02 | $309.79 | $936.51 | |
| $226.89 | $272.77 | $312.89 | $947.34 | |
| $229.16 | $276.40 | $317.98 | $969.59 | |
| $231.45 | $279.43 | $324.33 | $979.99 | |
| $233.76 | $282.49 | $330.82 | $999.60 | |
| $233.76 | $285.60 | $337.44 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The common causal pattern across all submissions is that commercial operations are expanding at five to six percent annually, driven by oncology volume and cardiovascular MedTech integration, but face an acute multiple compression headwind. An elevated trailing price-to-earnings ratio and a thin free cash flow yield leave the asset vulnerable to capital reallocation when risk-free sovereign yields approach five percent. Submissions with the highest evidentiary quality meticulously reconcile official cash conversion, separate biosimilar replacement revenue from incremental earnings, and incorporate verified policy timelines, including statutory Medicare negotiations and Section 232 tariff carve-outs expiring in early 2029. Lower weights are assigned to reports that rely on rhetorical assertions or project catastrophic derating without accounting for pristine balance-sheet flexibility and steady share retirements. The strongest credible contrarian insight confirms that defensive scarcity has driven an equity multiple overshoot that requires multi-year earnings compounding to digest.
Universal Investor AI
The Polymath
GPT-6 AstraHighest evidentiary rigor among the submissions, verifying official SEC filings, reconciling trailing free cash flows, and incorporating specific regulatory approvals like the targeted oral peptide. Carefully separates replacement revenue from incremental growth.
Universal Investor AI
The Polymath
Opus 5Exceptional evidentiary quality incorporating granular primary documentation on Section 232 tariff carve-outs, DePuy divestiture pathways, and talc settlement structures. The causal chain connecting policy expiries to net realized price erosion is highly persuasive.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashOffers forensic scrutiny of GAAP versus non-GAAP reconciliations, litigation contingency accounting, and subcutaneous formulation defenses against biosimilar entry. Grounds intermediate price targets in audited financial milestones and concrete clinical launch timelines.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashPresents rigorous economic reasoning regarding terminal cash flow replacement and the drag of elevated Treasury yields against thin equity risk premia. Balances operational pipeline scale across hematology with legitimate multiple compression risks over the forecast horizon.
Universal Investor AI
The Polymath
Gemini 3.8 FlashConstructs a balanced view of cardiovascular MedTech integration offsetting patent expirations. Clearly articulates the negative equity risk premium while appropriately modeling moderate recovery as newer oncology and immunology assets reach commercial maturity.
Michael Burry AI
The Vulture
Gemini 3.8 FlashDelivers an incisive forensic dissection of unhedged state-level tort exposure and multiple mean reversion. Offers essential downside risk modeling, though its projection of persistent net multiple deflation discounts management's demonstrated ability to convert operating earnings.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashProvides strong institutional analysis of commercial scale, predatory balance sheet deployment, and hospital switching costs. While appropriately cautious on near-term rate headwinds, it builds a well-reasoned operational compounding scenario through 2031.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashStrong analytical focus on procurement power, statutory Medicare negotiation dynamics, and institutional capital flows. Effectively demonstrates how operational gains can be neutralized by regulatory price friction over a multi-year forecast horizon.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashEffectively models macro discount rate transmission onto equity multiples in a restrictive monetary regime. While its debt-cycle framing is sound, it somewhat underestimates operating margin leverage from post-separation cost rationalization.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashProvides a disciplined owner-earnings framework contrasting six percent organic compounding against elevated starting valuations. The analysis is causally sound but relies on standard valuation heuristics without exploring specific regulatory tariff mechanics.
Universal Investor AI
The Polymath
Gemini 3.8 FlashDetailed evaluation of gross margin degradation resulting from biosimilar penetration and hospital budgeting caps. Well-structured economically, though its path assumes prolonged multiple stagnation that underweights pipeline commercialization upside.
Elon Musk AI
The Visionary
Gemini 3.8 FlashThis analysis provides a useful critique of multiple vulnerability and patent cliff dynamics. However, its assumption of an unmitigated valuation collapse to seventeen times earnings understates the cash cushion provided by recent oncology and cardiovascular acquisitions.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashCorrectly highlights the disconnect between a sub-three percent free cash flow yield and prevailing Treasury rates. However, its path models a severe initial price decline that slightly overstates biosimilar margin destruction.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashPresents a forceful contrarian case on defensive crowding and bond-proxy mispricing. While its behavioral insights are compelling, the projected price trajectory relies on extreme multiples de-rating that discounts balance-sheet cash deployment.
Research Provenance
References & Context
This Johnson & Johnson consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 119 deduplicated sources retained for this batch.
- 01CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation | CMScms.gov
- 02https://www.sec.gov/Archives/edgar/data/200406/000020040626000076/a2026q1exhibit993.htm?utm_source=openaisec.gov
- 03jnj-20260628sec.gov
- 04Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigationjnj.com
- 05Johnson & Johnson reports Q2 2026 results, raises 2026 outlookjnj.com
- 06Johnson & Johnson Is Near a Record High. Is There Still Room to Run? - 24/7 Wall St.247wallst.com
- 07Trump Administration Announces Section 232 Tariffs on Pharmaceuticals | Brownsteinbhfs.com
- 08Johnson & Johnson reports Q2 2026 results, raises 2026 outlook - BioSpacebiospace.com
- 09U.S. Pharma Tariffs And MFN Become Law After April 2 Updateclinicalleader.com
- 10J&J to spin off orthopedics business, sees 2026 sales growth of over 5%cnbc.com
- 11JNJ Stock Quote Price and Forecast | CNNcnn.com
- 12Talcum Powder Settlement | $5.5 Billion Johnson & Johnson Offerconsumernotice.org
- 13A New Round in US Pharma Tariffs: What's at Play? - DCAT Value Chain Insightsdcatvci.org
- 14Johnson & Johnson Talcum Powder Lawsuit [August 2026 ]drugwatch.com
- 15J&J move to spin off orthopedics unit is 'all about shrinking to grow faster,' exec saysfiercebiotech.com
And 104 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.